Laurus Labs Limited - Q1 FY2027 Earnings Call Summary Friday, July 24, 2026 12:30 PM GMT
Event Participants
Executives
4 Krishna Chaitanya Chava, Satyanarayana Chava, Soumya Chava, Vantaram Venkata Ravi Kumar
Analysts
11 Bharat Sheth, Dhawal Khut, Krish Mehta, Manoj Bahety, Mitul Mehta, Nitin Agarwal, Rehan Saiyyed, Sachin Jain, Sajal Kapoor, Tushar Manudhane, Vandit Dharamshi
Financials & KPIs
| Metric | Reported | Commentary |
|---|---|---|
| Total Revenue | ₹2,026 crores | +29% YoY; highest quarterly revenue ever, driven by CDMO commercial supplies and Affordable Medicines strength |
| CDMO Revenue (small molecule) | ₹835 crores | +69% YoY; acceleration in late-stage clinical and commercial deliveries for global partners across Human Health and Animal Health |
| Affordable Medicines Revenue | ₹1,156 crores | +10% YoY; volume-led growth in ARVs and Onco; new developed-market launches sustaining momentum |
| Bio Division Revenue | ₹35 crores | +21% YoY; customer diversification and pipeline progress in animal-origin-free and CDMO offerings |
| Gross Margin | 62.7% | +3.3pp YoY; +~2pp QoQ (61%→63%); favorable division mix and process improvements |
| EBITDA | ₹644 crores (31.8% margin) | Margin +7pp QoQ; capacity efficiency driven by growth in late-stage clinical and commercial projects |
| PAT | ₹368 crores | Highest quarterly profit |
| R&D Spend | 5.8% of revenue | +70% YoY; gene therapy and ADC technology infrastructure, complex pipeline building in Affordable Medicines |
| ROCE | ~19% | vs 17.7% prior year; continued improvement |
| CapEx (Q1 FY27) | ₹394 crores | FY27 guidance raised to ₹2,000 crores on customer demand visibility |
| Net Debt | ₹2,656 crores | Debt-to-EBITDA at 1.28x vs 1.25x QoQ; increase tied to CapEx plans; strong internal cash flows |
| ARV Revenue | ₹669 crores (API ₹415 cr + FDF ₹254 cr) | ARV:non-ARV mix at 1:2 in Affordable Medicines; ARV share expected to decline further |
| Cumulative Filings | 92 DMFs; 96 formulation dossiers | 2 formulation dossiers filed in Q1; 24 quality audits passed with no critical findings |
Geographic & Segment Commentary
CDMO (Small Molecule): Reported ₹835 crores, +69% YoY, driven by acceleration in late-stage clinical and commercial deliveries. Commercial supplies constituted 55% of CDMO revenue, with the balance largely Phase III supplies expected to convert to commercial. Business is well diversified by customer, product and therapeutic area with no high concentration risk; all CDMO programs are on-patent innovator molecules, with off-patent contract manufacturing captured under Affordable Medicines.
Affordable Medicines: Revenue of ₹1,156 crores, +10% YoY, driven by higher volumes across ARV and Onco portfolios where market leadership is maintained. Mix stands at 1/3 ARV and 2/3 non-ARV, with management expecting the non-ARV share to grow further. Fleet of 92 DMFs and 96 formulation dossiers; new South Africa office established to capture regional growth. New office in South Africa strengthens commercial presence in emerging markets.
Laurus Bio: Revenue of ₹35 crores, +21% YoY, broadly in line with expectations. ~20% of revenue comes from animal-origin-free cell culture ingredients and enzymes; ~60% from early-stage CDMO molecules spanning food proteins, colors and super absorbent polymers. Phase I commercial fermentation capacity of 400+ kiloliters at Vizag expected operational by end of CY2026; capacity is fungible across upstream/downstream programs.
Company-Specific & Strategic Commentary
CDMO Transformation: CDMO grew 69% to ₹835 crores with 55% commercial supply mix; management reaffirmed FY30 target of ≥50% of total revenue from CDMO, citing good visibility from Phase III programs converting to commercial.
ADC & New Modalities: Signed development and commercial agreement with Aarvik Therapeutics for 2 clinical-stage ADC molecules for India markets (MUTTA platform, both solid tumors). Licensed 2 preclinical assets with in vitro proof of concept completed; GLP toxicity studies expected to commence mid-next year. Also licensing patents from IIT Kanpur for gene therapy and invested in ImmunoACT for cell therapy capabilities.
Krka JV: Oncology formulation facility ready early next year; large-volume solid oral facility expected second half of CY2027. ₹400 crores invested to date; another ₹400 crores required, partially funded by partner loan.
Capacity & Infrastructure: Continued capacity creation at Vizag site and commercial-scale peptide capacity based on customer demand. Final handover of 500+ acres of AP government land parcel is in final stages. CapEx raised to ₹2,000 crores for FY27 on near-term partner capacity requirements across multiple products and customers.
ESG & Quality: Science-Based Targets Initiative (SBTi) validated near-term emission reduction targets in Q1; 24 regulatory and customer audits passed without critical findings.
Guidance & Outlook
| Metric | Guidance / Outlook | Commentary |
|---|---|---|
| CapEx FY27 | ₹2,000 crores | Raised successively from ₹1,000 cr → ₹1,500 cr → ₹2,000 cr; capacity for existing customers, expanding intermediates to API, new small-molecule modalities; multiple customers/products |
| CapEx FY27-28 | ≥₹3,000 crores combined | Earlier guidance of ₹3,000 crores for two years may be exceeded; no firm number shared |
| CDMO revenue share | ≥50% by FY30 | Management comfortable with FY30 target; Phase III programs converting to commercial provide visibility |
| CDMO run rate | Sustain current level ±₹100 crores (next 2 quarters) | High visibility on custom synthesis pipeline |
| Gross Margin | Maintain ~62-63% levels | Operating leverage expected to offset geopolitical input-cost pressures |
| Asset Turnover | >1.0x (first target) | Almost achieved; ROCE of 25% will take longer due to heavy CapEx cycle |
| ROCE | Continue improving from ~19% | Growth trajectory maintained; 25% target deferred |
| Fermentation Capacity | Phase I (400+ kL) operational end CY2026 | Construction on track; downstream processing infrastructure strengthening |
| Laurus Bio Ramp-up | Significant ramp-up in 12-18 months | Multiple programs under evaluation; 12-18 months crucial to identify winners |
| Krka JV | Oncology early next year; solid oral H2 CY2027 | Additional ₹400 crores CapEx, part funded by partner loan |
| Peptides | Meaningful revenue area | Multiple classes beyond GLP-1 being supported; commercial-scale capacity under construction |
Risks & Constraints
| Risk | Context |
|---|---|
| Geopolitical / Input Cost Inflation | Middle East/West Asia conflict pressuring raw material costs. Management acknowledges margin pressure but deems it not significant enough to alter the margin outlook. |
| CDMO Lumpiness & Commercial Conversion | 45% of CDMO revenue is Phase III/launch-prep supply, which carries conversion risk. One program already obtained approval; sustainability depends on continued regulatory approvals and commercial ramp-ups. |
| Bio/Fermentation Program Execution | Base business of ~₹200 crores is confident, but the next ramp-up depends on which fermentation programs succeed. Management flags 12-18 months as crucial; capacity fungibility is the mitigation. |
| Heavy CapEx Cycle Impact on Returns | ₹2,000 crores FY27 CapEx may pressure near-term ROCE and free cash flow. Net debt rose to ₹2,656 crores (debt/EBITDA 1.28x); 25% ROCE target pushed out. |
| Long Gestation of New Modalities | Gene therapy, ADC and cell therapy investments have 4-5 year payback periods; up to 10% of profits allocated to disruptive technologies with no near-term revenue contribution. |
Q&A Highlights
CapEx Guidance Revision
- Question: What changed in the last 6-8 months to nearly double CapEx guidance from ₹1,000 crores to ₹2,000 crores? Will FY28 guidance also change? (Vandit Dharamshi)
- Answer: CapEx increase is based on capacity requirements to meet customer demand. Expanding offerings from advanced intermediates to API and investing in new small-molecule modalities, driven by multiple customers and products, not a single engagement. FY27-28 combined CapEx may exceed earlier ₹3,000 crores guidance, but no firm number shared. (Satyanarayana Chava)
CDMO Growth Sustainability & Run Rate
- Question: Is late-stage molecule supply for anticipated approvals or already-approved products? What is the sustainable mix? (Tushar Manudhane)
- Answer: Mix of both launch preparation and post-approval supply. 55% of CDMO revenue is commercial; the 45% balance is largely Phase III supplies expected to convert to commercial. One Phase III program has already obtained approval. (Satyanarayana Chava, Krishna Chaitanya Chava)
- Question: Can the custom synthesis run rate be maintained? (Dhawal Khut)
- Answer: Fair to assume current run rate sustained within ±₹100 crores for the next two quarters. FY26 commercial contribution was 50% of CDMO revenue. (Krishna Chaitanya Chava)
Segment Mix — ARV vs Non-ARV
- Question: What is the ARV API vs FDF split, and is the 1/3–2/3 mix now stable? (Krish Mehta)
- Answer: ARV API ₹415 crores, ARV FDF ₹254 crores, total ARV ₹669 crores. ARV share at 1/3 is expected to decline further — it will not go up beyond this level. (Satyanarayana Chava, Soumya Chava)
Historical Investment Conviction (2023 Weak Period)
- Question: What gave you conviction to keep investing during the weak 2023 period when ROCE and margins were collapsing? (Sajal Kapoor)
- Answer: Customers want to see capacity before awarding products and avoid changing manufacturing sites to minimize regulatory complexity. Management invested aggressively but never at bankruptcy-level risk. FY23 large purchase order execution validated the capacity-first approach. CFO added: the team read Bhagavad Gita during the 7 weak quarters, maintained balance of mind, and continued investing — paying off for the last 5 quarters. (Satyanarayana Chava, Vantaram Venkata Ravi Kumar)
Capital Allocation Across Growth Horizons
- Question: How do you balance harvesting, scaling and seeding investments across horizons? (Sajal Kapoor)
- Answer: Advanced biologics (gene therapy, ADC) are conscious investments in faster-growing modalities; small-molecule investments are predictable. Up to 10% of profits allocated to disruptive technology. Any major investment in new areas takes 4-5 years — investing now is required for FY30 revenue growth. (Satyanarayana Chava, Vantaram Venkata Ravi Kumar)
Laurus Bio Predictability
- Question: How predictable is the precision fermentation business, including the 400+ kL Vizag capacity going commercial next year? (Sajal Kapoor)
- Answer: Current ~₹200 crores revenue is very confident. Next ramp-up depends on multiple products — not all will succeed, but not all will fail. Next 12-18 months will determine which molecules take off. Upstream/downstream capacity is fungible across programs. (Satyanarayana Chava)
FY30 CDMO Target & ForEx
- Question: Will the FY30 50% CDMO revenue target be prepone? What is ForEx gain? (Unknown Analyst, Ramesh Chand Jain)
- Answer: Comfortable with FY30 target of at least 50% revenue from CDMO. ForEx gain on balance sheet is ₹5 crores. Aarvik ADC programs are preclinical — GLP tox, IND filing, Phase I/II India trials will take 3-4 years to generate revenue. (Satyanarayana Chava, Vantaram Venkata Ravi Kumar)
CDMO Concentration & Molecule Scale
- Question: Are there molecules generating ₹200 crores+ in CDMO? How much could a blockbuster contribute? (Unknown Analyst, Ghanshyam Meena)
- Answer: Yes, there are molecules generating ₹200 crores+. Client blockbuster status doesn't directly translate to API supplier value — depends on dosage (500 mg/day vs 1-2 mg/day) and per-mg value. CDMO revenues are well diversified with no high customer, product or therapeutic-area concentration. (Krishna Chaitanya Chava)
Peptides & GLP-1
- Question: Have commercial-scale synthesizers been qualified for peptides? When meaningful revenue? (Rehan Saiyyed)
- Answer: Cannot discuss project-specific details. Peptides expected to be a meaningful area for Laurus; multiple classes of programs beyond GLP-1 are being supported, with details to follow in due course. (Krishna Chaitanya Chava, Satyanarayana Chava)
Krka JV Update
- Question: How much more CapEx is required for Krka JV and when will revenues start? (Manoj Bahety)
- Answer: Oncology facility ready early next year; solid oral facility in second half of CY2027. ₹400 crores invested so far; another ₹400 crores required, part of which will come as a loan from partner. (Satyanarayana Chava)
Key Takeaway
Laurus Labs delivered its highest-ever quarterly revenue (₹2,026 crores, +29% YoY), EBITDA (₹644 crores, 31.8% margin, +7pp QoQ) and PAT (₹368 crores) in Q1 FY27, driven by a 69% surge in small-molecule CDMO revenue to ₹835 crores — with commercial supplies at 55% of the mix — and 10% growth in Affordable Medicines to ₹1,156 crores. Management raised FY27 CapEx guidance to ₹2,000 crores (from ₹1,000 crores) on validated customer demand across multiple programs and products, reaffirmed the FY30 target of ≥50% revenue from CDMO, and guided the current CDMO run rate to sustain within ±₹100 crores over the next two quarters. Strategic investments continue across peptides, ADC (Aarvik Therapeutics agreement), gene therapy, fermentation (400+ kL Phase I online by end-CY2026) and the Krka JV, while ROCE improved to ~19%. Key watch points include conversion of the 45% Phase III CDMO revenue into commercial supplies, fermentation program success over the next 12-18 months, margin resilience amid geopolitical input-cost pressures, and the impact of the elevated CapEx cycle on near-term returns.